Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndrome. (Funded by Alexion Pharmaceuticals; C08-002 ClinicalTrials.gov numbers, NCT00844545 adults and NCT00844844 adolescents; C08-003 ClinicalTrials.gov numbers, NCT00838513 adults and NCT00844428 adolescents).